[{"orgOrder":0,"company":"Health Hope Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Encequidar","moa":"P-glycoprotein 1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Health Hope Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Health Hope Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Health Hope Pharma \/ Gilead Sciences"}]

Find Clinical Drug Pipeline Developments & Deals by Health Hope Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : HHP and Hanmi Pharm will grant Gilead exclusive global rights to encequidar, a first-in-class P-glycoprotein inhibitor, within the field of virology.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 29, 2025

                          Lead Product(s) : Encequidar

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Gilead Sciences

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank